Publications by authors named "Hua-Gang Liang"
Article Synopsis
- A study confirmed the survival benefits of icotinib, an EGFR tyrosine kinase inhibitor, for patients with advanced lung cancer and explored its use as post-surgery therapy for stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma.
- In the ICAPE trial, 79 patients took oral icotinib for 1.5 years after surgery, showing a median disease-free survival of 41.4 months and overall survival of 67.0 months during a median follow-up of 39.7 months.
- The study found no significant differences in disease-free survival based on specific mutations, suggesting icotinib could be a promising adjuvant treatment, but the ideal duration for its
The purpose of the present study was to evaluate the prognostic value of preoperative coagulation factor levels (including fibrinogen and D-dimer) and inflammatory indicators in patients with non-small cell lung cancer (NSCLC). The medical records of 456 patients with NSCLC who had undergone curative resection were retrospectively analysed. The recommended cut-off values for preoperative fibrinogen, neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio and lymphocyte-monocyte ratio were determined using receiver operating characteristic curve analyses.
View Article and Find Full Text PDFLung cancer is by far the leading cause of cancer death in the world. Despite the improvements in diagnostic methods, the status of early detection was not achieved. So, a new diagnostic method is needed.
View Article and Find Full Text PDF